ArticleJournal of clinical medicine2025
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases.
Vali Aliyev, Murad Guliyev, Murat Günaltılı, Mehmet Cem Fidan, Emir Çerme, Hamza Abbasov, Zeliha Birsin, Selin Cebeci, Nebi Serkan Demirci, Özkan Alan
Abstract read
In one paragraphArticle in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Vali AliyevDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0003-0947-9348 Murad GuliyevDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Murat GünaltılıDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0001-6116-3936 Mehmet Cem FidanDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Emir ÇermeDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Hamza AbbasovDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0003-1227-9996 Zeliha BirsinDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Selin CebeciDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Nebi Serkan DemirciDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Özkan AlanDepartment of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-6635-2012 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
bone metastasescancercost-effectivenessdenosumabskeletal-related events (SREs)zoledronic acid
Identifiers
PMID41010673
PMCPMC12470827
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390